Skip to main content
Equibles
CBIH logo

CBIH · Cannabis Bioscience International Holdings, Inc. · Metrics

Track CBIH — free

Use CBIH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBIH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Apr 16, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As indicated in Note 3 of the notes to the audited consolidated financial statements for the period ended February 28, 2026, and the report thereon of the Company's independent auditing firm, there is substantial doubt as to the ability of the Company to continue as a going concern.”
View the 10-Q filed Apr 16, 2026
Market Cap
$2.33M
Shares
11.63B
Volume · Sep 30 20K Avg daily vol (3M) 5.54M

CBIH metrics

52 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$2.33M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-33.3%
Price change (6M)
-50.0%
Price change (YTD)
-60.0%
Price change (1Y)
-50.0%
Trailing year
Price change (5Y)
-93.9%
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
-71.4%
Change from 52-week low
+100.0%
Annualized volatility
373.9%
Annualized volatility (3M)
—
Beta
-3.2
RSI (14D)
53.6
Price vs SMA 50
+13.6%
Price vs SMA 200
-45.4%
Avg volume (3M)
5.54M
Relative volume
0.0
Average dollar volume
$971

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
11.63B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
20.9×
reciprocal yield 4.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
18.8×
reciprocal yield 5.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
32.8×
reciprocal yield 3.1%
EV / revenue historical average (5Y)
32.8×
reciprocal yield 3.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
78.8%
Operating margin
-322.6%
Trailing 12 months
Net margin
-416.8%
Gross profit (TTM)
$97,394
Operating profit (TTM)
−$398,820
Net income (TTM)
−$515,288
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-25.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$123,627
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-33,373.6%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-2.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$264,002
Latest balance sheet
Cash & equivalents
$90
Total assets
$1,544
Total debt
$264,092

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$268,114
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
20 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1411057 CUSIP 16948K106 Visit website Investor relations